Dasatinib-d8 (CAS 1132093-70-9)

Dasatinib-d8 (CAS 1132093-70-9) References

1. Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study.  |  Iwamoto, T., et al. 2019. Ther Drug Monit. 41: 575-581. PMID: 31008998
2. Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors.  |  Izumi-Nakaseko, H., et al. 2020. Cardiovasc Toxicol. 20: 58-70. PMID: 31280457
3. Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma.  |  Mukai, Y., et al. 2020. J Chromatogr B Analyt Technol Biomed Life Sci. 1137: 121928. PMID: 31877431
4. To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry.  |  Veerman, GDM., et al. 2021. J Pharm Biomed Anal. 193: 113733. PMID: 33217707
5. Development of a Sensitive and High-Throughput Assay for Simultaneous Quantification of 5 Tyrosine Kinase Inhibitors and 2 Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry.  |  Sumimoto, T., et al. 2022. Ther Drug Monit. 44: 419-429. PMID: 34469417
6. A simple isotope-labeled UHPLC-MS/MS assay for simultaneous quantification of methotrexate, imatinib and dasatinib.  |  Zhang, Y., et al. 2021. Bioanalysis. 13: 1501-1510. PMID: 34601897
7. Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.  |  Ruigrok, EAM., et al. 2022. Int J Mol Sci. 23: PMID: 35887398
8. A liquid chromatography-tandem mass spectrometry method for simultaneous quantification of thirty-nine tyrosine kinase inhibitors in human plasma.  |  Guo, ZX., et al. 2023. J Pharm Biomed Anal. 224: 115159. PMID: 36442459
9. Quantitation of osimertinib, alectinib and lorlatinib in human cerebrospinal fluid by UPLC-MS/MS.  |  de Leeuw, SP., et al. 2023. J Pharm Biomed Anal. 225: 115233. PMID: 36638566
10. In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib.  |  Feijtel, D., et al. 2023. Cancers (Basel). 15: PMID: 36765883
11. Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors  |  , et al. 2020. Cardiovascular Toxicology. volume 20,: pages 58–70.
12. Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment  |  , et al. 2022,;. Int. J. Mol. Sci. 23(14),: 8037.
13. Development and Validation of a Simple Method for Simultaneously Measuring the Concentrations of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Blood Spot (DBS): A Pilot Study to Obtain Candidate Conversion Equations for Predicting Plasma Concentration Based on DBS Concentration  |  , et al. Number 6, December 2022,. Source: Therapeutic Drug Monitoring,. Volume 44,: 762-770(9).